Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations

CRANBURY, New Jersey, August 17, 2010 - Cornerstone Pharmaceuticals, Inc., the cancer metabolism company, today
announced that Dorit Arad, Ph.D., has been appointed director of research and
development for the company's operations in Israel. Cornerstone
Pharmaceuticals is establishing development and clinical research and trial
collaborations with leading scientists and physician investigators.
Cornerstone is the leader in the discovery and development of cancer
therapies based on the science of cancer metabolism.

Dr. Arad has more than 25 years of multidisciplinary experience in the
areas of industrial R&D, physical organic chemistry, computational chemistry,
drug design, bioinformatics, structural biology and biotechnology. She is the
author and co-author of 50 scientific publications as well as 30 patent
applications and has received several prestigious awards in chemistry. Dr.
Arad has collaborated and interacted with world-class scientists including
Nobel laureate Dr. John Pople, Dr. H.C. Brown, and Dr. Ada Yonat.

Prior to joining Cornerstone Pharmaceuticals, Dr. Arad founded NLC Pharma
Inc., Anticancer Israel and MND Diagnostics, LTD, the latter of which
developed a new high-speed test to detect swine flu. Dr. Arad also developed
a unique mechanism based technology (QCT) as Executive VP of Drug Design for
Exegenics Inc. in Dallas, TX. As a professor of molecular microbiology and
biotechnology at Tel-Aviv University, she pioneered the field of molecular
modeling and drug design in Israel and provided consulting services to
leading Israeli pharmaceutical companies including Teva, Dipharm, NST,
Gamidor-Gamida and Gamida-cell. Early in her career, Dr. Arad earned her
B.S., M.S. and D.Sc. in chemistry from the Technion-Israel Institute of
Technology.

"Dr. Arad is a renowned expert in structure-based drug design," remarked
Dr. Robert Shorr, CEO for Cornerstone Pharmaceuticals. "Based on her long and
successful track record in a variety of disciplines, we have great confidence
in her contributions to our drug discovery efforts, specifically, in her
ability to optimize the clinical development of CPI-613, a first-in-class
cancer-fighting drug currently in clinical trials that targets certain key
aspects of cancer metabolism. I am extremely pleased to add her experience
and skill set to our executive management team."

"I am proud to spearhead Cornerstone's operations in Israel and to assist
in the management of its development and clinical efforts here," said Dr.
Arad. "Cancer is a devastating disease, with very few treatment options and
represents a huge health challenge in Israel. The chance to work with the
most advanced clinical programs and leading scientists in cancer metabolism
is extremely exciting. I look forward to helping to bring to market drugs
that may positively impact the lives of patients."

About Cancer Metabolism

Cancer cell metabolism is an exciting and promising area for the
development of drugs to treat cancer. While it has been known for nearly a
century that cancer cells have a unique metabolism, only recently has there
been a broad and significant renewal of scientific interest focused on
exploring this unique metabolic difference to facilitate the discovery and
development of groundbreaking therapies. Cornerstone is the only company that
currently has a drug in clinical trials targeting certain key enzymes that it
has identified as crucial to cancer cell metabolism. Unlike normal cell
metabolism, cancer cell metabolism utilizes less oxygen and has different
nutritional requirements to survive and proliferate. This metabolic
difference is considered to be fundamental to the transformation of normal
cells into cancer cells and is believed to be conserved in all cancers,
including solid tumors, lymphoma and leukemia. By better understanding these
cancer-specific metabolic processes, researchers in the field hope to find
new drugs to revolutionize cancer treatment.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc., the leading cancer metabolism company,
is committed to changing the way cancer is treated through the discovery and
development of innovative therapies capitalizing on the unique metabolic
processes of cancer cells. The company's founding members, management and
scientific advisory team include pre-eminent scientists focused on cancer
cell metabolism, cancer research and drug development. Cornerstone is unique
in that it currently has a first-in-class drug in clinical trials that
targets key enzymes crucial to cancer cell metabolism. AEMD, the company's
unique approach to cancer treatment, is the leading platform in cancer
metabolism. It has facilitated the discovery of first-in-class drugs with the
potential to transform the way cancer is treated. Cornerstone's lead drug,
CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II
clinical trials in a variety of tumor types.

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel
mechanism, targets metabolic changes considered to be common to many, if not
all, cancer types and not present in normal cells. Patients with solid tumors
and hematologic cancers are currently being enrolled in multiple Phase I and
Phase I/II human clinical trials evaluating CPI-613. These trials include a
Phase I/II single agent trial for patients with solid tumors who have failed
all other therapy options, a Phase I/II combination trial with Gemcitabine in
newly diagnosed or relapsed patients, and a single agent trial in hematologic
malignancies. CPI-613 was granted orphan drug status by the US FDA for
pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes
undetected in its early stages.

For further information, visit www.cornerstonepharma.com. Or
contact: Meghan Weber at +1-917-399-8713

This release contains forward-looking statements. These statements relate
to future events or each company's future financial performance. In some
cases, you can identify forward-looking statements by terminology such as
"may", "will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" or "continue", the negative of such terms,
or other comparable terminology. These statements are only predictions.
Actual events or results may differ materially from those in the
forward-looking statements as a result of various important factors. Although
we believe that the expectations reflected in the forward-looking statements
are reasonable, such statements should not be regarded as a representation by
the company, or any other person, that such forward-looking statements will
be achieved. The business and operations of the company are subject to
substantial risks which increase the uncertainty inherent in forward-looking
statements. We undertake no duty to update any of the forward-looking
statements, whether as a result of new information, future events or
otherwise. In light of the foregoing, readers are cautioned not to place
undue reliance on such forward-looking statements.

    Cornerstone Pharmaceuticals, Inc          Media Contact: Meghan Weber
    1 Duncan Drive                            Liza Sullivan & Associates
    Cranbury, NJ 08512                        +1-917-399-8713

Meghan Weber, Liza Sullivan & Associates, +1-917-399-8713